Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy
- Author:
Takashi MIWA
1
;
Mitsuro KANDA
;
Chie TANAKA
;
Daisuke KOBAYASHI
;
Masamichi HAYASHI
;
Suguru YAMADA
;
Goro NAKAYAMA
;
Masahiko KOIKE
;
Yasuhiro KODERA
Author Information
- Publication Type:Original Article
- Keywords: Gastric cancer; S-1; Adjuvant chemotherapy; Biomarker; Albumin-bilirubin score
- MeSH: Chemotherapy, Adjuvant; Drug Therapy; Gastrectomy; Hematologic Tests; Humans; Odds Ratio; Retrospective Studies; Stomach Neoplasms
- From:Journal of Gastric Cancer 2019;19(2):183-192
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Due to adverse events, dose reduction or withdrawal of adjuvant chemotherapy is required for some patients. To identify the predictive factors for tolerability to postoperative adjuvant S-1 monotherapy in gastric cancer (GC) patients, we evaluated the predictive values of blood indicators. MATERIALS AND METHODS: We analyzed 98 patients with pStage II/III GC who underwent postoperative adjuvant S-1 monotherapy. We retrospectively analyzed correlations between 14 parameters obtained from perioperative routine blood tests to assess their influence on the withdrawal of postoperative adjuvant S-1 monotherapy, within 6 months after discontinuation. RESULTS: Postoperative adjuvant chemotherapy was discontinued in 21 patients (21.4%) within 6 months. Univariable analysis revealed that high preoperative albumin-bilirubin (ALBI) scores had the highest odds ratio (OR) for predicting the failure of adjuvant S-1 chemotherapy (OR, 6.47; 95% confidence interval [CI], 2.08–20.1; cutoff value, –2.696). The high ALBI group had a significantly shorter time to failure of postoperative adjuvant S-1monotherapy (hazard ratio, 3.48; 95% CI, 1.69–7.25; P=0.001). Multivariable analysis identified high preoperative ALBI score as an independent prognostic factor for tolerability (OR, 10.3; 95% CI, 2.33–45.8; P=0.002). CONCLUSIONS: Preoperative ALBI shows promise as an indicator associated with the tolerability of adjuvant S-1 monotherapy in patients with pStage II/III GC.
